Cibc World Markets Corp Acquires 5,735 Shares of Agilent Technologies, Inc. (NYSE:A)

Cibc World Markets Corp increased its position in Agilent Technologies, Inc. (NYSE:A - Free Report) by 14.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,340 shares of the medical research company's stock after buying an additional 5,735 shares during the quarter. Cibc World Markets Corp's holdings in Agilent Technologies were worth $6,091,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of A. Flynn Zito Capital Management LLC grew its position in Agilent Technologies by 3.8% in the fourth quarter. Flynn Zito Capital Management LLC now owns 1,871 shares of the medical research company's stock worth $251,000 after buying an additional 69 shares during the last quarter. IFP Advisors Inc lifted its position in shares of Agilent Technologies by 17.7% during the 4th quarter. IFP Advisors Inc now owns 458 shares of the medical research company's stock valued at $62,000 after acquiring an additional 69 shares during the last quarter. Tiemann Investment Advisors LLC boosted its stake in shares of Agilent Technologies by 5.6% during the 4th quarter. Tiemann Investment Advisors LLC now owns 1,423 shares of the medical research company's stock worth $191,000 after acquiring an additional 75 shares in the last quarter. Brown Brothers Harriman & Co. grew its holdings in shares of Agilent Technologies by 13.5% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company's stock worth $96,000 after acquiring an additional 77 shares during the last quarter. Finally, Rothschild Investment LLC raised its position in shares of Agilent Technologies by 19.2% during the fourth quarter. Rothschild Investment LLC now owns 491 shares of the medical research company's stock worth $66,000 after purchasing an additional 79 shares during the period.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on A shares. Barclays upgraded Agilent Technologies from an "underweight" rating to an "equal weight" rating and increased their price target for the company from $135.00 to $145.00 in a research report on Monday, February 10th. Robert W. Baird decreased their target price on shares of Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating for the company in a report on Thursday, February 27th. JPMorgan Chase & Co. cut their price target on shares of Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating on the stock in a report on Tuesday, November 26th. Sanford C. Bernstein decreased their price objective on shares of Agilent Technologies from $140.00 to $135.00 and set a "market perform" rating for the company in a research note on Tuesday, November 26th. Finally, Wells Fargo & Company cut their target price on shares of Agilent Technologies from $157.00 to $155.00 and set an "overweight" rating on the stock in a research note on Monday, December 9th. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $146.15.

Insider Buying and Selling

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the firm's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the transaction, the chief executive officer now directly owns 39,652 shares in the company, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Rodney Gonsalves sold 1,908 shares of Agilent Technologies stock in a transaction on Monday, March 17th. The stock was sold at an average price of $121.98, for a total transaction of $232,737.84. Following the completion of the transaction, the vice president now owns 21,786 shares in the company, valued at $2,657,456.28. This trade represents a 8.05 % decrease in their position. The disclosure for this sale can be found here.

Agilent Technologies Stock Up 1.0 %

NYSE A traded up $1.21 on Monday, reaching $121.96. The stock had a trading volume of 1,557,411 shares, compared to its average volume of 1,684,041. Agilent Technologies, Inc. has a 1 year low of $117.17 and a 1 year high of $155.35. The business has a 50 day moving average price of $136.74 and a 200 day moving average price of $137.28. The company has a current ratio of 2.20, a quick ratio of 1.66 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $34.77 billion, a price-to-earnings ratio of 28.04, a P/E/G ratio of 3.39 and a beta of 1.11.

Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.27 by $0.04. The firm had revenue of $1.68 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. On average, analysts forecast that Agilent Technologies, Inc. will post 5.57 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be paid a $0.248 dividend. This represents a $0.99 annualized dividend and a dividend yield of 0.81%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies's payout ratio is presently 22.76%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.